Skip to main content

Table 4 Summary of ongoing clinical trials of immune therapies in patients with hepatocellulars carcinoma (HCC)

From: Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Type of immunotherapyMoleculesNCT numberPhasePopulationEstimated enrollmentRecruitment status
Anti-PD-1PembrolizumabNCT03062358IIIAdvanced HCC, pre-treated450Recruiting
 NivolumabNCT02576509IIIAdvanced HCC, naive1720Active, not recruiting
  NCT03383458IIIResected HCC530Recruiting
Combinations      
Anti-PD-1 + Anti CTLA-4Durvalumab + tremelimumabNCT03298451IIIAdvanced HCC, naive1310Recruiting
 Nivolumab + ipilumumabNCT03510871IIEligible for curative surgery40Not yet recruiting
  NCT03222076IIResected HCC45Recruiting
Angiogenesis and ICINivolumab + bevacizumabNCT03382886IAdvanced HCC, pre-treated12Active, not recruiting
 Nivolumab + lenvatinibNCT03418922IAdvanced HCC, pre-treated and naive30Active, not recruiting
 Pembrolizumab + lenvatinibNCT03713593IIIAdvanced HCC, naive750Recruiting
Transarterial chemoembolization and ICINivolumabNCT03572582IIIntermediate stage HCC49Recruiting
 Durvalumab + tremelimumabNCT03638141IIIntermediate stage HCC30Recruiting
Y90-Radioembolization and Anti-PD-1NivolumabNCT03033446IIAdvanced HCC40Recruiting
  1. CTLA-4 Cytotoxic T lymphocyte-associated protein 4; ICI immune checkpoint inhibitors; PD-1 programmed cell death-1; PD-L1 Programmed death-ligand 1